Skip to content

Author

Marat Fudim

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Initial Diuretic Strategy During Hospitalization for Heart Failure and Associated Outcomes: Insights from the TREAT-AHF Registry.

BACKGROUND Real-world data regarding diuretic strategies and associated outcomes in patients hospitalized for heart failure (HF) in community health systems are limited. OBJECTIVES Evaluate associations between initial diuretic therapy, markers of decongestion, and clinical outcomes in patients hospitalized for HF. METHODS Patients hospitalized for HF from 2015-2022 across 30 health systems in the U.S. were identified in the Truveta national database. High dose loop diuretics were defined as >2.5X home dose or >160 mg IV furosemide equivalent over 24 hours. Four study groups were defined based on most intensive diuretic strategy used within 48 hours of admission: 1) high dose loop diuretics with adjuvant therapy (thiazide or acetazolamide), 2) high dose loop diuretics alone, 3) low dose loop diuretics with adjuvant therapy, and 4) low-dose loop diuretics alone. Multivariable logistic and linear regression models adjusted for clinical and demographic covariates were developed to evaluate associations between initial diuretic strategies and both in-hospital outcomes (acute kidney injury [AKI]), hemoconcentration, and weight change) and the composite of readmission or death. RESULTS Patients were treated with low dose loop diuretics (N=81,734; 74.9%), high dose loop diuretics (N=17,187; 15.7%), low dose loop diuretics plus adjuvant therapy (N=7,027; 6.4%), and high dose loop diuretics plus adjuvant therapy (N=3,210; 2.9%). Patients treated with more intensive strategies had greater illness severity, including more frequent prior HF hospitalizations and worse kidney function. Adjusted weight loss during hospitalization was greater for patients treated with more intensive strategies (high dose loop with adjuvant: 4.6 lbs [4.0-5.2]; high dose loop alone: 2.1 lbs [1.9-2.4]; low dose loop with adjuvant: 1.4 lbs [1.0-1.8]), as were adjusted odds of AKI. The adjusted odds of 90-day readmission/death were not lower with more intensive initial diuretic strategies. However, odds of 90-day readmission/death were lower for every 5 lbs of achieved weight loss (adjusted odds ratio: 0.97, 95% confidence interval 0.96-0.97). CONCLUSIONS More intensive diuretic strategies were used in sicker patients, improved in-hospital decongestion, but were not associated with improved 90-day outcomes. However, greater weight loss was associated with modestly lower risk of death or readmission. These data highlight the need for prospective studies to evaluate if enhancing decongestion can improve outcomes in patients hospitalized for HF.

A. Varshney, A. Ambrosy, Adam Furst et al. · 0 citations
Open access Aug 2026

Differential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II Trial.

BACKGROUND In the C-MIC II trial, C-MIC therapy improved outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We evaluated whether differences in background HF medication adjustments influenced the observed benefits. METHODS Ambulatory patients with chronic non-ischemic HFrEF receiving guideline-directed medical therapy (GDMT) were enrolled. The primary outcome was change in GDMT and diuretic intensity over 6 months. Treatment effects on left ventricular ejection fraction (LVEF), Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), and 6-minute walk distance (6MWD) were assessed by baseline sodium-glucose cotransporter-2 inhibitor (SGLT2i) use for consistency. RESULTS Among 65 patients, 25 (39%) had GDMT adjustments (C-MIC device: 44%; control 33%; p= 0.390). GDMT intensity increased in controls (Δ +0.36) but decreased (Δ -0.16; p= 0.100) in C-MIC group. Diuretic intensity decreased in C-MIC group (Δ -0.10) but increased in controls (Δ +0.12; p= 0.200). When stratified by baseline SGLT2i use, C-MIC therapy induced consistent improvements in LVEF (SGLT2i: +6% [95% CI 3-9; p<0.001] vs. without SGLT2i: +4% [95% CI 2-7; p=0.003]), KCCQ-OSS (SGLT2i: +42 points [95% CI 26-58; p<0.001] vs. without SGLT2i: +40 [95% CI 28-51; p<0.001]) and 6MWD (SGLT2i: +150 meters [95% CI 88-212; p<0.001] vs. without SGLT2i: +141 meters (95% CI 63-219; p<0.001]). CONCLUSION Medication intensity decreased in C-MIC-treated patients but increased in controls, driven primarily by escalation of diuretics, likely reflecting worsening HF. Consistent improvements in LVEF, 6MWD and KCCQ-OSS across SGLT2i subgroups suggest that the observed benefits are independent of background pharmacologic intensification.

Marat Fudim, T. Kovacevic-Preradovic, D. Kosevic et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.